HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Adenocarcinoma

Subscribe to New Research on Adenocarcinoma

A malignant epithelial tumor with a glandular organization.

Also Known As:

Adenocarcinomas; Adenocarcinomas, Basal Cell; Adenocarcinomas, Granular Cell; Adenocarcinomas, Oxyphilic; Adenocarcinomas, Tubular; Adenomas, Malignant; Basal Cell Adenocarcinoma; Basal Cell Adenocarcinomas; Carcinomas, Cribriform; Carcinomas, Granular Cell; Carcinomas, Tubular; Cribriform Carcinoma; Cribriform Carcinomas; Granular Cell Adenocarcinoma; Granular Cell Adenocarcinomas; Granular Cell Carcinoma; Granular Cell Carcinomas; Malignant Adenoma; Malignant Adenomas; Oxyphilic Adenocarcinoma; Oxyphilic Adenocarcinomas; Tubular Adenocarcinoma; Tubular Adenocarcinomas; Tubular Carcinoma; Tubular Carcinomas; Adenocarcinoma, Basal Cell; Adenocarcinoma, Granular Cell; Adenocarcinoma, Oxyphilic; Adenocarcinoma, Tubular; Adenoma, Malignant; Carcinoma, Cribriform; Carcinoma, Granular Cell; Carcinoma, Tubular

Networked: 33015 relevant articles (950 outcomes, 4483 trials/studies) for this Disease, Comments

Relationship Network

Disease Context: Research Results

Neoplasms: 516559
- Neoplasms by Histologic Type: 1
  - Glandular and Epithelial Neoplasms: 284
    - Carcinoma: 105989
      - Adenocarcinoma: 33015
        Hepatocellular Carcinoma: 34292
        Renal Cell Carcinoma: 10476
        Carcinoid Tumor: 3754
        Cholangiocarcinoma: 2347
        Choriocarcinoma: 2343
        Noninfiltrating Intraductal Carcinoma: 1683
        Ductal Carcinoma: 1483
        Adenoid Cystic Carcinoma: 844
        Adrenocortical Carcinoma: 768
        Mucinous Adenocarcinoma: 637
        Endometrioid Carcinoma: 584
        Lobular Carcinoma: 519
        Neuroendocrine Carcinoma: 370
        Mucoepidermoid Carcinoma: 357
        Bronchiolo-Alveolar Adenocarcinoma: 291
        Acinar Cell Carcinoma: 256
        Clear Cell Adenocarcinoma: 251
        Papillary Adenocarcinoma: 231
        Extramammary Paget Disease: 230
        Cystadenocarcinoma: 212
        Signet Ring Cell Carcinoma: 190
        Islet Cell Carcinoma: 136
        Scirrhous Adenocarcinoma: 82
        Eccrine Porocarcinoma: 41
        Klatskin's Tumor: 35
        Ovine Pulmonary Adenomatosis: 15
        Follicular Adenocarcinoma: 7
        Sebaceous Adenocarcinoma: 2
        Skin Appendage Carcinoma: 1

Related Diseases

1.	Neoplasms (Cancer)
2.	Neoplasm Metastasis (Metastasis)
3.	Carcinoma (Carcinomatosis)
4.	Squamous Cell Carcinoma (Epidermoid Carcinoma)
5.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

Experts

1.	Yeo, Charles J: 38 articles (12/2011 - 01/2002)
2.	Hruban, Ralph H: 37 articles (08/2012 - 01/2002)
3.	Friess, Helmut: 32 articles (03/2012 - 04/2002)
4.	Abbruzzese, James L: 29 articles (08/2012 - 05/2002)
5.	Beer, David G: 28 articles (08/2012 - 09/2002)
6.	Epstein, Jonathan I: 27 articles (03/2012 - 09/2002)
7.	Yang, Pan-Chyr: 26 articles (01/2013 - 11/2002)
8.	Cameron, John L: 26 articles (08/2012 - 01/2002)
9.	Maitra, Anirban: 25 articles (11/2012 - 08/2002)
10.	Büchler, Markus W: 24 articles (11/2012 - 04/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Adenocarcinoma:

1.	Fluorouracil (Carac)FDA LinkGeneric 07/01/2006 - "There is a threshold 5-FU dose after which the efficacy is dramatically improved-in mice bearing Colon 26 adenocarcinoma, that threshold is a dose of >150 mg/kg/week, and the increased efficacy correlates with about a fourfold increase in the AUC of 5-FU. " 07/01/2010 - "Hence, DPD inhibitory fluorouracil, such as S-1, may have potent therapeutic efficacy for poorly-differentiated adenocarcinoma of the colorectum." 07/01/2004 - "Sustained complete remission of metastatic oesophageal adenocarcinoma using long-term therapy with 5-fluorouracil." 12/01/2007 - "Adjuvant, 5-fluorouracil (5-FU)-based chemoradiotherapy for completely resected high-risk gastric adenocarcinoma has been shown to improve survival in a randomized Intergroup trial. " 07/01/1992 - "The results revealed that 5-FU or CDDP alone were ineffective for both GC-YN, a well differentiated adenocarcinoma line, and GC-SF, a poorly differentiated adenocarcinoma line; however, UFT was effective for GC-SF. " Order ALL the reference details at left...
2.	gefitinib (Iressa)FDA Link 02/01/2011 - "[A case of lung adenocarcinoma with postoperative recurrence maintaining complete remission by treatment with gefitinib]." 07/01/2009 - "We expected positive results from gefitinib, because the patient fitted the optimal profile: female, never smoker, adenocarcinoma histology. " 01/01/2007 - "[A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib]." 08/01/2012 - "Significantly improved survival was found in the gefitinib group compared with the control in the subgroup of patients with lung adenocarcinoma [hazard ratio = 0.89 (0.81, 0.99); P = 0.03], but not found in the subgroup of patients with EGFR mutant [hazard ratio = 0.87 (0.68, 1.12); P = 0.28]. " 04/01/2012 - "Gefitinib has shown high response rate and improved progression-free survival (PFS) in never-smokers with lung adenocarcinoma (NSLAs). " Order ALL the reference details at left...
3.	Cisplatin (Platino)FDA LinkGeneric 04/01/2004 - "Primary radiation with weekly cisplatin may be the best option for patients with stage IB(2) to IIA cervical adenocarcinoma. " 08/01/2011 - "Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy." 09/01/1982 - "The survival of asynchronous rat ovarian adenocarcinoma cells (ROT68/C1) treated for 1 hr with more than 0.5 microgram/ml of cis-diamminedichloroplatinum (II) (Cisplatin) revealed a marked decrease in a dose-dependent manner, as estimated by the vitro colonyforming method. " 03/01/2012 - "In conclusion, this study shows frequent overexpression of AURKA and suggests that MLN8237 could be an effective antitumor agent, which can be combined with cisplatin for a better therapeutic outcome in esophageal adenocarcinomas." 01/01/2012 - "In this study, we aimed to assess the expression of Ku80 in clinical lung adenocarcinoma specimens, and investigate its role in the regulation of cisplatin sensitivity in cisplatin resistant human lung adenocarcinoma cells A549/DDP. " Order ALL the reference details at left...
4.	gemcitabine FDA Link 01/01/2006 - "Clinically relevant improvement in QOL from baseline was observed more often after PEFG than after gemcitabine, suggesting that the PEFG regimen did not impair QOL, Partial response was associated with improved QOL suggesting that effective treatment of pancreatic adenocarcinoma may have an important role in these patients." 04/01/1999 - "One such therapy uses gemcitabine (GemzarR), an antimetabolite approved in 1996 by the Food and Drug Administration (FDA) for first-line treatment of locally advanced (nonresectable stage II or stage III) or metastatic (stage IV) adenocarcinoma of the pancreas. " 01/01/2003 - "Phase II studies have suggested an improved response rate and acceptable toxicity profile associated with gemcitabine combinations compared to gemcitabine alone for treatment of metastatic adenocarcinoma of the pancreas. " 11/01/2002 - "Therefore, a phase II study was conducted to evaluate the efficacy of gemcitabine combined with radiation therapy in patients with localized unresectable adenocarcinoma of the pancreas. " 07/01/2011 - "While gemcitabine-based regimens are currently accepted as the standard first-line treatment of patients with locally advanced or metastatic pancreatic adenocarcinoma, there is no consensus regarding treatment in the second-line setting. " Order ALL the reference details at left...
5.	Paclitaxel (Taxol)FDA LinkGeneric 03/01/2001 - "Weekly paclitaxel was very well tolerated, yet was effective for recurrent cervical adenocarcinoma." 07/01/2007 - "Paclitaxel also has a high response rate for undifferentiated-type adenocarcinoma, and can be expected to show high efficacy for peritoneal dissemination. " 03/01/2001 - "Remission of metastatic cervical adenocarcinoma with weekly paclitaxel." 08/01/1996 - "To evaluate the efficacy of paclitaxel administered to patients with unresectable adenocarcinomas of the gallbladder and biliary tree over 3 hours every 21 days. " 01/30/2013 - "In the cellular uptake studies, PTX-OPHPC brought about a significantly higher amount of PTX accumulated in human breast adenocarcinoma cell line (MCF-7 cells) compared with Taxol(®). " Order ALL the reference details at left...
6.	Carboplatin (JM8)FDA LinkGeneric 06/01/2010 - "The purpose of the present study is to observe the role of volume-sensitive Cl(-) channels in carboplatin-induced apoptosis in the human lung adenocarcinoma cell line A549 cells. " 01/01/2003 - "The aim of this study was to investigate the efficacy and toxicity of carboplatin given as monotherapy in endometrial adenocarcinoma. " 10/01/1988 - "A phase II study of carboplatin in adenocarcinoma of the oesophagus." 12/01/1985 - "Phase II trial of carboplatin in patients with adenocarcinomas of the upper gastrointestinal tract." 06/01/2010 - "Activation of volume-sensitive Cl(-) channel is involved in carboplatin-induced apoptosis in human lung adenocarcinoma cells." Order ALL the reference details at left...
7.	Epidermal Growth Factor Receptor (EGF Receptor)IBA 11/01/2010 - "Our understanding of the central role of epidermal growth factor receptor in the development and progression of lung adenocarcinoma has led to the development of molecular agents against this key oncogene that have demonstrated significant clinical efficacy against the disease. " 06/01/2005 - "Association between epidermal growth factor receptor mutation and improved survival in never-smokers with primary adenocarcinoma of the lung." 11/01/2012 - "Molecular studies revealed no evidence of epidermal growth factor receptor mutation, a molecular alteration which may be found in primary pulmonary adenocarcinoma." 06/01/2012 - "Amplification of the human epidermal growth factor receptor 2/neu (HER2/neu) gene and overexpression of the HER2 protein (HER2) have been shown to occur in gastric and gastroesophageal junction adenocarcinoma in a number of studies. " 05/01/2012 - "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial." Order ALL the reference details at left...
8.	Leucovorin (Folinic Acid)FDA Link 09/01/1998 - "The objective of this trial was to determine the activity and evaluate the toxicity of UFT plus oral calcium leucovorin in patients with advanced pancreatic adenocarcinoma. " 05/01/2005 - "Standard-dose external radiation and oral UFUR plus leucovorin were used to treat 30 middle and lower rectal adenocarcinoma patients. " 04/01/1992 - "In vivo antitumor effects of fluoropyrimidines on colon adenocarcinoma 38 and enhancement by leucovorin." 06/01/1990 - "Protein-bound folates were also detected in HT29 human colon adenocarcinoma cells grown in 5-formyltetrahydrofolate (maximum, 11 pmol/mg protein). " 05/15/1989 - "Expansion of CH2THF pools in tissues of BALB/c mice bearing s.c.-implanted EMT6 mammary adenocarcinomas was measured after leucovorin administration. " Order ALL the reference details at left...
9.	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/01/2012 - "Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation." 11/01/2009 - "Univariate analysis revealed that long term survival was associated with a Charlson's score < or = 2, PS 0-1, a normal white blood cell count at diagnosis, adenocarcinoma histology, response (RP) to first line treatment and treatment with a tyrosine-kinase inhibitor (TKI). " 12/01/2010 - "The aim of the present study was to investigate the prognostic and predictive role of EGFR and KRAS analysis in advanced lung adenocarcinomas, selected according to clinical features associated to better response to EGFR tyrosine kinase inhibitors (TKIs), namely female gender and non-smoker or former light smoker status. " 02/01/2006 - "In the previous studies, we examined mutation status in the tyrosine kinase domain of EGFR, exon18 through exon21, in 112 primary lung adenocarcinoma samples. " 06/17/2004 - "To study the abnormity and clinical value of tyrosine kinase signaling pathway in lung adenocarcinoma. " Order ALL the reference details at left...
10.	Doxorubicin (Adriamycin)FDA LinkGeneric 04/01/2003 - "A549 lung adenocarcinoma cells, in which p53 was eliminated with the HPV16 E6 gene, exhibited efficient arrest in the G2 phase when treated with adriamycin. " 01/01/1990 - "In organotypic cultures (nodules) of A 549 human lung adenocarcinoma cells, the long-term cytotoxicity of Adriamycin is strongly improved by shortening the exposure time to the drug. " 01/01/2012 - "This study investigated the molecular mechanism by which GT suppresses the growth of doxorubicin-resistant lung adenocarcinoma H23/0.3 cells. " 01/08/2004 - "In this study, bacterial ghosts from Mannheimia haemolytica were used for site-specific delivery of doxorubicin (DOX) to human colorectal adenocarcinoma cells (Caco-2). " 12/01/2000 - "Female B6C3F1 mice with transplanted mammary adenocarcinoma were divided into four randomized groups and injected with 10 mg/kg adriamycin on day 7 of the study. " Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/2012 - "Complete remission from advanced-stage synchronous double primary (SDP) esophageal and gastric adenocarcinoma by chemotherapy alone is rare. " 12/01/2011 - "We present a unique case of metastatic mixed adenocarcinoma/SCC of the prostate, in which the patient survived more than 36 months with complete remission after initiation of aggressive hormonal and chemotherapy. " 08/01/2010 - "Recent retrospective and prospective studies have helped to clarify the optimal chemotherapy approach for advanced small bowel adenocarcinoma. " 05/01/2009 - "Recent retrospective and prospective studies have helped to clarify the optimal chemotherapy approach for advanced small bowel adenocarcinoma. " 12/15/2004 - "To assess the role of TP53 status in predicting pathologic complete remission after primary chemotherapy in patients with ethmoidal intestinal-type adenocarcinoma (ITAC). " Order ALL the reference details at left...
2.	Radiotherapy 11/01/2012 - "Objective To evaluate the efficacy of transanal excision (TAE) combined with radiotherapy for rectal adenocarcinoma, assess the ability of pretreatment endoscopic ultrasound (EUS) to predict failures, and determine the prognostic value of downstaging and complete pathological response. " 11/01/2010 - "To examine the efficacy of vaginal vault radiotherapy as adjuvant treatment for patients with high-grade, stage I/II endometrial adenocarcinoma who have been surgically staged. " 07/01/2002 - "Good outcome for patients with adenocarcinoma of the rectum who undergo neoadjuvant external beam radiotherapy and proctectomy is associated with subspecialty training in colon and rectal surgery." 06/01/1999 - "A high ratio of apoptosis to proliferation correlates with improved survival after radiotherapy for cervical adenocarcinoma." 11/01/1996 - "We defined the efficacy of radiotherapy for the treatment of high grade (Gleason scores 8 to 10) adenocarcinoma of the prostate. " Order ALL the reference details at left...
3.	Heterologous Transplantation (Xenotransplantation) 03/01/2010 - "NTD has also been proven to be highly effective in vivo to inhibit the growth of both murine and human lung adenocarcinoma in a subcutaneous xenograft model without any deteriorating side effect. " 03/27/2008 - "In particular, compound 48 demonstrated significant antitumor efficacy against established HT29 human colon adenocarcinoma xenografts implanted in athymic mice. " 01/01/1995 - "SPAC showed higher therapeutic efficacy against human colorectal adenocarcinoma xenografts than against human gastric and lung adenocarcinoma xenografts. " 01/01/1992 - "The present data therefore demonstrate the importance of (1) higher doses of [6RS]LV, (2) expansion of pools of CH2-H4PteGlun+H4PteGlun, and (3) dThd salvage capability in potentiation of the therapeutic efficacy of FUra in colon adenocarcinoma xenografts. " 07/01/2004 - "To examine the efficacy of this HRE-Egr-TK gene therapy in vivo, the A549 adenocarcinoma xenografts were planted in BALB/c nude mice. " Order ALL the reference details at left...
4.	Esophagectomy 10/01/2003 - "Complete pathologic response to induction chemoradiation is associated with improved early overall and disease-free survival following esophagectomy for adenocarcinoma of the distal esophagus. " 07/01/2009 - "Laparoscopic inversion esophagectomy is a safe and effective approach to the treatment of high-grade dysplasia and early esophageal adenocarcinoma. " 02/01/2010 - "Intramucosal adenocarcinoma can be effectively treated with endoscopic resection techniques and with less morbid surgical options including a vagal-sparing esophagectomy. " 08/01/2011 - "Our study shows that LA-THE is feasible, safe, and effective in the treatment of adenocarcinoma of the esophagus and GEJ and should probably be considered an alternative to open esophagectomy and other minimally invasive techniques in the treatment of this disease." 03/15/2005 - "Our study showed that patients with esophageal or EGJ adenocarcinoma who have signet-ring cell or mucinous histology benefited substantially from preoperative chemoradiation and esophagectomy." Order ALL the reference details at left...
5.	Combination Drug Therapy (Combination Chemotherapy) 01/01/2008 - "In the treatment of unresectable, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma, no chemotherapy combination was accepted as the gold standard. " 07/01/2012 - "Information from randomized trials on the role of combination chemotherapy in the adjuvant treatment of pancreatic adenocarcinoma is limited. " 03/26/2011 - "Data from two large, randomized phase III trials support the use of perioperative combination chemotherapy in lower oesophageal and oesophagogastric junction adenocarcinomas, but the contribution of the adjuvant therapy is uncertain. " 12/01/2002 - "Most studies of single-agent or combination chemotherapy in the treatment of patients with advanced adenocarcinoma of the pancreas have documented low response rates and little reproducible impact on patient survival or quality of life. " 04/01/1985 - "A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma." Order ALL the reference details at left...

blog comments powered by Disqus

TREATMENT OPTIONS
for Adenocarcinoma,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 950 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>